Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Adrenocortical Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The adrenocortical carcinoma market is on a growth trajectory, with projections showing an increase from $3.76 billion in 2025 to $3.92 billion in 2026, at a CAGR of 4.4%. This growth stems from heightened diagnosis through imaging technologies, an expansion of specialized cancer research centers, and increased patient awareness. Looking toward 2030, the market is expected to reach $4.62 billion, with a CAGR of 4.2%, supported by advancements in targeted therapies and minimally invasive procedures, as well as the adoption of combination therapy protocols. The rise in the prevalence of rare cancers is a significant driver of this market's expansion. Advances in diagnostic technologies have improved early detection, especially in rare cancer types like adrenocortical carcinoma (ACC), which are aggressive and have specific diagnostic and
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]Yahoo! Finance
- Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]TheStreet.com
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratoriesPR Newswire